Literature DB >> 12654737

Therapeutic potential of neutralizing antibodies in the treatment of HIV-1 infection.

Gabriela Stiegler1, Hermann Katinger.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12654737     DOI： 10.1093/jac/dkg172

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN： 0305-7453            Impact factor:   5.790


× No keyword cloud information.
  8 in total

1.  Pharmacokinetics and Preliminary Safety of Pod-Intravaginal Rings Delivering the Monoclonal Antibody VRC01-N for HIV Prophylaxis in a Macaque Model.

Authors:  Chunxia Zhao; Manjula Gunawardana; Francois Villinger; Marc M Baum; Mariana Remedios-Chan; Thomas R Moench; Larry Zeitlin; Kevin J Whaley; Ognian Bohorov; Thomas J Smith; Deborah J Anderson; John A Moss
Journal:  Antimicrob Agents Chemother       Date:  2017-06-27       Impact factor: 5.191

2.  sCD4-17b bifunctional protein: extremely broad and potent neutralization of HIV-1 Env pseudotyped viruses from genetically diverse primary isolates.

Authors:  Laurel A Lagenaur; Vadim A Villarroel; Virgilio Bundoc; Barna Dey; Edward A Berger
Journal:  Retrovirology       Date:  2010-02-16       Impact factor: 4.602

3.  The broadly neutralizing anti-human immunodeficiency virus type 1 4E10 monoclonal antibody is better adapted to membrane-bound epitope recognition and blocking than 2F5.

Authors:  Nerea Huarte; Maier Lorizate; Rubén Maeso; Renate Kunert; Rocio Arranz; José M Valpuesta; José L Nieva
Journal:  J Virol       Date:  2008-07-02       Impact factor: 5.103

4.  An oligosaccharide-based HIV-1 2G12 mimotope vaccine induces carbohydrate-specific antibodies that fail to neutralize HIV-1 virions.

Authors:  Joseph G Joyce; Isaac J Krauss; Hong C Song; David W Opalka; Karen M Grimm; Deborah D Nahas; Mark T Esser; Renee Hrin; Meizhen Feng; Vadim Y Dudkin; Michael Chastain; John W Shiver; Samuel J Danishefsky
Journal:  Proc Natl Acad Sci U S A       Date:  2008-10-06       Impact factor: 11.205

5.  Identification and characterization of a new cross-reactive human immunodeficiency virus type 1-neutralizing human monoclonal antibody.

Authors:  Mei-Yun Zhang; Xiaodong Xiao; Igor A Sidorov; Vidita Choudhry; Fatim Cham; Peng Fei Zhang; Peter Bouma; Michael Zwick; Anil Choudhary; David C Montefiori; Christopher C Broder; Dennis R Burton; Gerald V Quinnan; Dimiter S Dimitrov
Journal:  J Virol       Date:  2004-09       Impact factor: 5.103

6.  Recognition of membrane-bound fusion-peptide/MPER complexes by the HIV-1 neutralizing 2F5 antibody: implications for anti-2F5 immunogenicity.

Authors:  Nerea Huarte; Aitziber Araujo; Rocio Arranz; Maier Lorizate; Heribert Quendler; Renate Kunert; José M Valpuesta; José L Nieva
Journal:  PLoS One       Date:  2012-12-21       Impact factor: 3.240

Review 7.  The antigenome: from protein subunit vaccines to antibody treatments of bacterial infections?

Authors:  Carmen Giefing; Eszter Nagy; Alexander von Gabain
Journal:  Adv Exp Med Biol       Date:  2009       Impact factor: 2.622

8.  Focal accumulation of aromaticity at the CDRH3 loop mitigates 4E10 polyreactivity without altering its HIV neutralization profile.

Authors:  Edurne Rujas; Daniel P Leaman; Sara Insausti; Pablo Carravilla; Miguel García-Porras; Eneko Largo; Izaskun Morillo; Rubén Sánchez-Eugenia; Lei Zhang; Hong Cui; Ibon Iloro; Félix Elortza; Jean-Philippe Julien; Christian Eggeling; Michael B Zwick; Jose M M Caaveiro; José L Nieva
Journal:  iScience       Date:  2021-08-17
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.